Related Experiment Videos

5-HT2A antagonists in psychiatric disorders

Luisa de Angelis1

  • 1Department of Biomedical Sciences, University of Trieste, Italy. ldeangelis@spin.it

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed

Insights

Serotonin (5-HT) system abnormalities are linked to psychiatric disorders. Selective 5-HT2A antagonists show promise for treating psychosis and drug dependence by modulating dopamine activity.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Serotonergic (5-HT) system dysregulation is implicated in the pathophysiology of various psychiatric conditions.
  • The 5-HT2A receptor is a key target for understanding and treating these disorders.

Purpose of the Study:

  • To review the association between the 5-HT2A receptor gene and psychiatric disorders.
  • To explore the therapeutic potential of selective 5-HT2A antagonists in psychiatric and substance use disorders.

Main Methods:

  • Literature review synthesizing evidence on 5-HT2A receptor gene associations.
  • Analysis of studies investigating 5-HT2A antagonists in psychiatric and addiction models.

Main Results:

  • Evidence links the 5-HT2A receptor to schizophrenia, major depression, and obsessive-compulsive disorder.
  • Selective 5-HT2A antagonists demonstrate potential in treating psychosis, alcohol, and cocaine dependence.
  • 5-HT2A receptor antagonism contributes to the efficacy of atypical antipsychotics and antidepressants.

Conclusions:

  • Selective 5-HT2A antagonists may offer novel therapeutic strategies for psychosis and drug dependence.
  • These agents modulate dopamine activity, suggesting antipsychotic properties without affecting basal tone.
  • Further understanding of 5-HT2A receptor function is crucial for developing new treatments.

Related Concept Videos